Biotechnology facts and figures

Biotechnologies are a strategic sector – from both an economic and social point of view – on an international scale: biological products currently represent 40% of the total registered products and if we take into account chemical medicines developed with biotechnologies,

we can estimated than over 50% of the new medicines originate from them, notably the most innovative medicines (insulin, growth hormones, recombinant growth factors, vaccinations, monoclonal antibodies for the treatment of cancers, inflammatory and infectious diseases, cell therapy, etc) and almost 250 million patients worldwide are already benefiting from advances made in biotechnologies, both in diagnostics and in treatment.

Small and medium-sized biotechnology firms (3,500 worldwide, approximately 250 to 300 in France) together with researchers are renewing the pipeline of the therapeutic products available to doctors and patients, undertaking cutting-edge research and using the very latest technologies.

The fields of application of biotechnologies are extremely varied, and beyond human or animal health, biotechnology firms are also developing innovative applications in various industrial fields, in environmental protection and in agri-business, in particular.